Navigation Links
Conference Call Advisory - NUCRYST Pharmaceuticals Corp. Conference Call to Discuss 2009 First Quarter Results
Date:4/29/2009

                           Wednesday, May 6, 2009
                                9:00 a.m. EDT

                               1-800-814-4860

                Webcast:http://www.nucryst.com/web_casts.htm

CALGARY, April 29 /PRNewswire-FirstCall/ - NUCRYST Pharmaceuticals Corp. invites analysts and investors to participate in a briefing on Wednesday, May 6, 2009, with David B. Holtz, Interim President & Chief Executive Officer, and Chief Financial Officer, regarding the Company's 2009 first quarter results.

The briefing, via conference call, is set for 9:00 a.m. EDT. To participate, please call the toll-free number 1-800-814-4860. In addition to standard disclosure over wire services, a news release with the first quarter results will be posted on the NUCRYST web site prior to the call. To listen to the call live on the Internet, please go to http://www.nucryst.com/web_casts.htm.

The briefing will be recorded and available for re-broadcast on demand for seven days by dialing 1-877-289-8525. Callers will need to provide the operator with the following reservation number: 21305201 followed by the number sign. An audio file of the call will also be archived on the NUCRYST web site.

About NUCRYST Pharmaceuticals

NUCRYST Pharmaceuticals Corp. (NASDAQ: NCST; TSX: NCS) develops, manufactures and commercializes medical products that fight infection and inflammation using SILCRYST(TM), its patented atomically disordered nanocrystalline silver technology. NUCRYST licensed world-wide rights for SILCRYST(TM) wound care coating products to Smith & Nephew plc, which markets these products in over 30 countries under their Acticoat(TM) trademark. NUCRYST has developed its proprietary nanocrystalline silver in a powder form, referred to as NPI 32101, for use in medical devices and as an active pharmaceutical ingredient.

    Acticoat(TM) is a trademark of Smith & Nephew plc
    SILCRYST(TM) is a trademark of NUCRYST Pharmaceuticals Corp.


'/>"/>
SOURCE NUCRYST Pharmaceuticals Corp.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
2. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
3. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
4. GPhAs 2007 Annual Policy Conference Features Top Generic Industry CEOs; FDA, Government Officials; Wall Street Analysts
5. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
6. Omnicell to Present at Thomas Weisel Healthcare Conference 2007
7. AtriCure to Present at Roth Capital Partners 2007 New York Conference
8. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
9. MDS to Present at Thomas Weisel Partners Healthcare Conference
10. Hospira to Present at the Bear Stearns 20th Annual Healthcare Conference on September 11
11. AMICAS to Present at Thomas Weisel Partners Healthcare Conference 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... ... August 17, 2017 , ... Dr. Charles ... Through Forgiveness ($15.99, paperback, 9781498497626; $7.99, eBook, 9781498497633) focuses on the treatment ... of memories and achieve forgiveness, through a progressive journey toward healing. This book ...
(Date:8/17/2017)... , ... August 17, 2017 , ... Momkus McCluskey ... newest Partner. Ms. Parks is a member of the firm’s Commercial Litigation and Employment ... and provides a wealth of knowledge in matters of employment litigation, commercial litigation and ...
(Date:8/17/2017)... ... , ... A recent report indicates that circa 79 percent of 483 warning ... data integrity. The FDA outlines their expectations for quality critical instrumentation in the GMP ... the Beckman Coulter Life Sciences Virtual Trade Show Virtual Event, this webinar ...
(Date:8/16/2017)... ... August 16, 2017 , ... Blue Health Intelligence (BHI) ... President, Chief Medical Officer. Dr. Spiro brings over 30 years of clinical, healthcare IT, ... for BHI’s cutting-edge analytics solutions. , “I am thrilled to welcome Dr. Spiro ...
(Date:8/16/2017)... ... August 16, 2017 , ... The Data Council, ... that it was acquired by Advantage Solutions. The Data Council’s IX-ONE platform ... include the industry’s leading suppliers, brokers, distributors and retailers. The Data Council will ...
Breaking Medicine News(10 mins):
(Date:8/17/2017)... -- Bio-Ess Laboratories, LLC Chief Science Officer, Dr. Adam Elhofy , ... on Cell-Ess® Universal Titer Boost at the 9 th ... August 21-25.  The Bioprocessing Summit convenes more than 1,000 international bioprocess professionals ... ... Cell-Ess is ...
(Date:8/15/2017)... -- AccuGenomics, Inc., a diagnostic company based in ... company has provided an AccuKit to the HIV Cure ... Hill and to Qura Therapeutics for evaluation in HIV ... reservoir and viral expression in human CD4+ T cells ... is a joint initiative between the University of North ...
(Date:8/10/2017)... -- Physical Rehabilitation Network (PRN), acquired the long-standing outpatient rehabilitation clinic, ... . The reputable clinic will continue to be co-owned and ... staff of four clinicians. Lipkin received his doctorate in physical ... years of experience with a strong background in manual therapy. ... 10th PRN clinic in and around the Denver ...
Breaking Medicine Technology: